46 results about "Diabetic complication" patented technology

The invention belongs to the technical field of artificial intelligence, and discloses a diabetic complication risk deduction system based on a graph neural network and a knowledge graph, and the system comprises a physiological feature sensing module which collects physiological sensing data of a diabetic patient, carries out the time synchronization and normalization processing of the physiological sensing data, and carries out the prediction of the diabetic complication risk. Separating a stability characteristic component and a disturbance characteristic component; the pathological potential mapping module is used for mapping the stable characteristic component into a basic physiological node and mapping the disturbance characteristic component into a potential pathological activation node on the basis of a semantic structure of a knowledge graph, introducing a pathological potential function and establishing a pathological potential mapping network; the pathology activation recognition module calculates potential pathology energy of each potential pathology activation node in the pathology potential mapping network through a graph neural network, and when the potential pathology energy is greater than a preset potential pathology energy threshold, the potential pathology activation node is marked as a pathology activation source node; and early warning of diabetic complications is realized.

The present application relates to heterobicyclic compounds having glucagon-like peptide receptor (GLP-1R) agonist activity, processes for their preparation, pharmaceutical compositions comprising them and their use as GLP-1R agonists or for the treatment or prophylaxis of GLP-1R associated diseases or disorders. In particular, the compounds of the present application are useful for body weight management, for lowering blood sugar and / or for the treatment or prevention of diabetes, diabetic complications, obesity, overweight, dyslipidemia, fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)), metabolic diseases, cardiovascular diseases, nervous system disorders, mental disorders, kidney diseases, etc. , gastrointestinal diseases, autoimmune diseases, inflammatory diseases, lung diseases, hypothalamic-pituitary-gonad axis related diseases or disorders, cancers and the like.

The invention discloses a traditional Chinese medicine composition for treating type 2 diabetes and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from, by weight, 11-15 parts of radix acanthopanacis semticosi, 5-15 parts of male silkworm moth, 7-17 parts of white ginseng, 5-11 parts of rhizoma polygoni cuspidati, 15-25 parts of rhizoma coptidis, 1-5 parts of cortex cinnamomi, 11-15 parts of fructus ligustri lucidi, 11-15 parts of common fenugreek seed, 7-17 parts of lithocarpus litseifolius, 3-7 parts of raw radix astragali and 1-3 parts of wild lucid ganoderma. , 3-9 parts of tribulus terrestris and 11-17 parts of nigella nigra seeds. The traditional Chinese medicine composition has the effect of balancing and stabilizing blood sugar, is short in treatment course, quick in effect and free of toxic and side effects, and has an excellent curative effect on treating diabetic complications.

The application provides a traditional Chinese medicine compound medicine composed of Coptis chinensis, Astragalus membranaceus, Panax notoginseng and Rehmannia glutinosa and application thereof in preventing and treating diabetes and diabetes complications, and experimental results show that the compound medicine has good prevention and treatment effects on diabetes and various diabetes complications such as diabetic heart disease, diabetic kidney disease and diabetic retinopathy.

The application discloses a diabetes complication risk assessment method based on unequal length CGM data and belongs to the field of assessment methods. The application aims to solve the problem of how to extract the complication-related features from the unequal length CGM sequence of a diabetes patient and realize efficient risk assessment without losing dynamic information as much as possible. The application comprises the following steps: step 1, acquiring a multi-day CGM data sequence of a diabetes patient; step 2, performing feature extraction based on the multi-day CGM data sequence to obtain multi-day CGM sequence features; and step 3, inputting the multi-day CGM sequence features into an FCNN to obtain the probability of the diabetes patient suffering from complications. C ; step 3, inputting the multi-day CGM sequence features C into an FCNN to obtain the probability of the diabetes patient suffering from complications.

The present invention relates to novel compounds and pharmaceutical compositions thereof, and to methods for promoting healthy skin aging, treating skin disorders, treating cardiovascular disorders, treating renal disorders, treating angiogenesis disorders, such as cancer, treating tissue damage, such as non-cardiac tissue damage, treating progressive myocardial infarction, and treating various other disorders, such as complications resulting from diabetes with the compounds and compositions of the invention. Other disorders may include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, skin infections, peripheral vascular disease, stroke, and the like.

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof:wherein each symbol means the same as that described in the specification.

This invention belongs to the field of artificial intelligence technology. It discloses a risk prediction system for diabetic complications based on graph neural networks and knowledge graphs. The system includes a physiological feature perception module, which collects physiological perception data from diabetic patients, performs time synchronization and normalization on the data, and separates stable and perturbation feature components; a pathological potential mapping module, which, based on the semantic structure of the knowledge graph, maps stable feature components to basic physiological nodes and perturbation feature components to potential pathological activation nodes, introduces a pathological potential function, and establishes a pathological potential mapping network; and a pathological activation identification module, which calculates the potential pathological energy of each potential pathological activation node in the pathological potential mapping network using a graph neural network. When the potential pathological energy exceeds a preset potential pathological energy threshold, it is marked as a pathological activation source node; thus achieving early warning of diabetic complications.

The invention relates to the technical field of diabetic complication prediction, and discloses a modeling method of a diabetic complication prediction model. The method comprises the following steps: collecting clinical index data of a patient, including blood glucose level, blood pressure value, blood fat content and renal function parameters, and performing standardization processing to generate a standard data set; time sequence features in the data set are extracted, the short-term fluctuation trend and the long-term change rule of each index are calculated through a sliding window algorithm, and a time sequence feature vector is generated; and inputting the vector into a deep feature extraction network formed by multilayer convolution and long and short term memory units, and extracting high-dimensional time sequence feature representation. Based on the representation, a hierarchical clustering algorithm is used for grouping patient groups, and personalized complication risk prediction sub-models are constructed for different groups. And integrating the outputs of all the personalized sub-models, and generating a final diabetic complication prediction result through a weighted voting mechanism.

This invention discloses an optimization method and system for a predictive model of diabetic complications. It involves collecting routine laboratory test data from diabetic patients, performing preprocessing such as missing value removal, label merging, and SMOTE resampling to construct a balanced dataset. The average importance of indicators is evaluated using multiple machine learning models to select a subset of key features. Random forest, XGBoost, support vector machine, and multilayer perceptron are selected as base classifiers, and after hyperparameter optimization, a stacked ensemble learning model is constructed to further improve predictive performance. Finally, the model is packaged as an API service and embedded into a hospital information system to achieve high-precision, low-cost, and real-time risk prediction of diabetic complications. Experimental results show that this invention achieves an accuracy of 98.5% and an AUC of 99.76% in predicting diabetic nephropathy complications, outperforming single models.

The present application relates to the preparation of new physiological and pharmaceutically active molecules, and belongs to the field of pharmaceutical synthesis chemistry, and relates to the design and preparation of a class of molecules capable of inhibiting the activity of human kallikrein. Firstly, fluoroacrylic acid and alcohol compounds are used as raw materials to obtain a class of fluoroallyl alcohol compounds; then the fluoroallyl alcohol is condensed with carboxylic acid compounds to obtain fluoroallyl carboxylic acid ester compounds with general formula (I) capable of inhibiting the activity of human kallikrein. The compounds are considered to be useful for treating diabetic complications, eye diseases and edema-related diseases. In addition, they have potential applications in the diagnosis and treatment of some cancers.

The invention provides a pharmaceutical active ingredient composition and application thereof in treating diabetes or preventing and treating diabetic complications. The pharmaceutical active ingredient composition provided by the invention comprises a first active ingredient and a second active ingredient, the first active component is at least one of the following components: a DPP-4 inhibitor, pharmaceutically acceptable salts, esters, prodrugs and metabolites thereof, and an SGLT-2 inhibitor, pharmaceutically acceptable salts, esters, prodrugs and metabolites thereof; the second active ingredient is at least one of the following components: coenzyme Q10, pharmaceutically acceptable ester of the coenzyme Q10, R-alpha-lipoic acid, pharmaceutically acceptable salt and ester of the R-alpha-lipoic acid, glutathione, pharmaceutically acceptable salt of the glutathione, resveratrol and pharmaceutically acceptable ester of the resveratrol. The pharmaceutical active ingredient composition provided by the invention has a good hypoglycemic effect, and has remarkable advantages in the aspects of relieving oxidative stress and preventing and treating diabetic complications.

The invention discloses onium salt derivatives containing tetrahydropyran side chains as well as a preparation method and application of the onium salt derivatives. The structure of the compound also comprises isomers, solvates and pharmaceutically acceptable salts thereof, and the compound has good inhibitory activity on alpha-glucosidase, and can improve glycolipid metabolism disorder of diabetic nephropathy model mice and protect renal functions. The compound enriches the structure type of the existing alpha-glucosidase inhibitor, and has the potential of preventing or treating hyperglycemia, diabetic complications, obesity, abnormal lipid metabolism or hypertension.

We provide safe mitochondrial uncoupling agents. [Solution] The present invention provides 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole, a novel phenyl derivative, or a pharmaceutically acceptable salt thereof. This compound is useful for regulating mitochondrial activity, reducing obesity, and treating diseases including diabetes and diabetic complications.

The invention belongs to the field of biological pharmacy, and relates to a dipeptidyl peptidase IV inhibitory oligopeptide and application thereof. Specifically, the DPP-IV inhibitory peptide is designed by computer-aided design. The polypeptide with DPP-IV inhibitory activity is screened out through virtual amino acid mutation, online database prediction, molecular docking and other methods. The invention proves that the LAFPGSW polypeptide can obviously improve the physiological indexes of diabetic mice, has no toxic or side effect, and can relieve the change of mouse liver weight and mouse body weight caused by diabetes, so that the mouse liver weight and the mouse body weight are recovered to a normal level; according to the present invention, the compound can significantly reduce the levels of AST, ALT, TC and TG in serum, and relieve LDL-C and HDL-C abnormality, such that the compound has effects of blood sugar lowering, lipid lowering, insulin secretion promoting, insulin resistance improving and the like, and can be used for prevention and treatment of diabetes and diabetic complications.

The invention belongs to the technical field of disease treatment, and particularly relates to a composition for regulating blood sugar and microvascular homeostasis and a preparation method thereof. The composition for regulating the blood sugar and the microvascular homeostasis is prepared from the following components in parts by mass: 380 to 520 parts of peony seed oil, 260 to 440 parts of dihydromyricetin and 0.025 to 0.062 part of chromium picolinate. The composition for regulating blood sugar and microvascular homeostasis can be used for protecting microvessels, regulating blood sugar, improving microcirculation of the whole body and preventing diabetic complications, and is suitable for preventing and treating diseases such as hyperglycemia, hyperlipidemia and glycolipid metabolism syndrome. Experiments on vascular endothelial dysfunction of obese rats show that the composition disclosed by the invention can be used for remarkably improving microvascular endothelial functions of the obese rats and effectively delaying rise of arterial blood pressure. Experiments on mouse diabetic cardiomyopathy find that the composition has a definite myocardial protection effect on DCM mice.

The invention provides a pharmaceutical composition for treating diabetic complications and application thereof. Research finds that after effective parts such as coptis chinensis and radix puerariae are combined, the composition has obvious influence on diabetic complications and has a certain treatment effect. Specifically, the invention provides application of a coptis chinensis and kudzu vine root composition in preparation of a medicine for treating diabetic skin ulcer. The rhizoma coptidis and radix puerariae composition is prepared from the following raw materials in parts by weight: 1 to 10 parts of rhizoma coptidis alkaloid and 1 to 10 parts of rhizoma coptidis polysaccharide; the kudzuvine root extract is prepared from 1-10 parts by weight of kudzuvine root flavone, 1-10 parts by weight of kudzuvine root polysaccharide and 1-10 parts by weight of kudzuvine root saponin.

The invention belongs to the technical field of medicine, and provides a traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preventing and treating diabetes mellitus, the traditional Chinese medicine composition comprises concha arcae, radix scrophulariae, rhizoma anemarrhenae, ginseng, radix astragali, prepared rehmannia root, dogwood, Chinese yam, moutan bark, poria cocos, radix puerariae, rhizoma atractylodis, radix salviae miltiorrhizae, earthworm, stiff silkworm and rhizoma alismatis. The invention provides a novel pharmaceutical composition for preventing and treating diabetes, which is reasonable in formula and exact in curative effect. The traditional Chinese medicine composition not only can effectively reduce blood sugar and improve core symptoms of diabetes mellitus, but also can treat diabetic complications in a targeted manner, especially can achieve synergistic prevention and treatment of diabetic feet, and solves the limitation that most of existing medicines only aim at a single symptom.

This invention discloses a diabetes complication risk prediction system based on disease prior masks, belonging to the field of diabetes risk assessment technology. By designing a disease relationship learning module based on pathology masks, irrational disease interactions are suppressed and inter-task information flow that violates medical logic is shielded. This forces the model to learn only clinically meaningful shared representations, reducing the risk of learning incorrect associations under noisy data and significantly enhancing the model's medical interpretability, making its internal decision-making mechanism highly consistent with clinical pathological mechanisms. Furthermore, the introduced relationship attention gating mechanism adaptively adjusts the fusion ratio between disease relationship information and task-specific features according to the needs of different complication tasks, enhancing beneficial relationship signals when necessary and automatically suppressing irrelevant features when noise is high. This achieves more stable and efficient multi-task feature interaction and collaborative learning, enabling more accurate prediction of diabetes complications.

The application discloses a tetrahedral framework nucleic acid targeting RAGE, which is a tetrahedral framework nucleic acid carrying siRNA; and the sequence of the siRNA is shown as SEQ ID NO. 5-6. By carrying specific siRNA on specific TDNs, the application effectively and continuously down-regulates the expression of RAGE, blocks the NF-kappa B channel, inhibits the expression of macrophage inflammatory factors, and plays a whole-body anti-inflammatory and anti-oxidation function. In addition, the application can also regulate the pyroptosis state of macrophages through the NLRP3 / Caspase-1 axis, maintain the microenvironment homeostasis and inhibit the spread of cell death signals, so as to realize the prevention and treatment of diabetic complications and diseases related to advanced glycation end products. In-vivo experiments also prove that the application has a therapeutic effect on the whole-body pathological tissue damage of diabetic mice. The nucleic acid nanomedicine has practical popularization and application value.

The invention discloses nutrition powder capable of reducing blood sugar and preventing diabetic complications and a preparation method of the nutrition powder. The nutrition powder comprises the following components in parts by weight: 20-45 parts of tartary buckwheat flour, 15-35 parts of highland barley flour, 1-8 parts of psyllium husk powder, 1-5 parts of oat beta-glucan, 1-4 parts of inulin, 0.2-1 part of aspartame, 10-25 parts of medicinal and edible food powder and 1-15 parts of medicinal and edible plant extract. Through reasonable compatibility of the tartary buckwheat, the highland barley, the oat beta-glucan, the inulin, the medicinal and edible food, the medicinal and edible food extract and the psyllium seed husk powder, a diabetic patient can have satiety, the intake of food is reduced, the postprandial blood sugar is balanced, the fasting blood-glucose level of the patient can be reduced, islet cells are favorably repaired, and the diabetes mellitus can be effectively treated. Meanwhile, diabetic complications can be prevented.

The invention relates to the technical field of medical prediction, in particular to an intelligent deduction service method and system for the morbidity process of diabetic complications, and the method comprises the steps: collecting continuous blood glucose monitoring, heart rate variability and skin electrical activity data of a user; based on the heart rate variability and the skin electrical activity data, an emotional pressure index for quantifying the autonomic nerve excitation degree is calculated; inputting the continuous blood glucose data and the emotional pressure index into a deduction rule knowledge base containing a medical production rule for reasoning; obtaining brain function risk and / or blood sugar control difficulty assessment; and generating visual report feedback containing personalized pressure-reducing non-drug intervention suggestions. According to the method, multiple data are fused, reasoning is conducted through a medical rule base, the problems that single-index early warning lags and machine learning black boxes lack interpretability are solved, brain function risks are prospectively deduced, the influence of pressure on blood glucose control is quantified, adverse circulation is broken, and intervention suggestions with physiological bases are provided.

The invention provides a diabetic complication identification method based on an exhaled gas biomarker combination. A marker is selected from one or more of isoprene, acetone, isopropanol, benzene, toluene, ethylbenzene, p-xylene, undecane and tetradecane. The invention provides a safe, convenient, efficient and non-invasive diagnosis method so as to monitor the health condition of the human body in time, thereby providing a new thought and method for early diagnosis, treatment and prevention of the human body.

The application relates to the field of artificial intelligence, and discloses a diabetes complication risk prediction method, which comprises the following steps: acquiring clinical medical data and intestinal microorganism sequencing data of historical diabetes patients; calculating evolutionary distances between intestinal flora based on the sequencing data, and acquiring an abundance matrix according to the evolutionary distances; inputting the abundance matrix into a prediction model to obtain a feature vector; merging and convolving the feature vector and the clinical indexes of the historical diabetes patients to obtain a prediction probability; comparing the prediction probability with real labels of the historical diabetes patients, adjusting model parameters of the prediction model, and obtaining an optimized model; and predicting the complication risk of a current diabetes patient based on the optimized model according to a complication query demand of the current diabetes patient. The application further discloses a diabetes complication risk prediction device, an electronic device and a storage medium. The application can improve the accuracy of diabetes complication risk prediction.

The invention belongs to the technical field of Chinese herbal medicines, and particularly relates to a traditional Chinese medicine herbal composition for preventing and treating diabetic complications and a preparation method thereof. The traditional Chinese medicine herbal composition is prepared from folium mori, radix astragali, radix rehmanniae, radix polygonati officinalis, radix ophiopogonis, rhizoma dioscoreae, poria cocos, radix puerariae, opuntia ficus-indica, inulin, rumex hanus, American ginseng and rhizoma curcumae longae. The traditional Chinese medicinal materials are combined to clean sugar scale micro-crystals in blood vessel microcirculation, improve the functions of liver and pancreas islet, regulate the blood sugar level and enhance the anti-oxidation and self-healing capability of a body, so that the blood sugar is stabilized; the occurrence of diabetic complications such as fundus retinopathy, neuropathy, hypertension, cerebral infarction, myocardial infarction, uremia and gangrene is prevented and controlled. Besides, the traditional Chinese medicine composition is a pure herbal traditional Chinese medicine formula, is high in safety and exact in curative effect, and has a wide application prospect in the field of prevention and treatment of diabetic complications.

This invention belongs to the field of pharmacology and provides the application of demethoxycurcumin and phlorizin in the preparation of drugs that inhibit β-lactoglobulin glycosylation. The synergistic inhibitory effects and mechanisms of demethoxycurcumin and phlorizin on AGEs were systematically investigated. Fluorescence spectroscopy and carbonyl / thiol / amino group assays confirmed that demethoxycurcumin and phlorizin can synergistically inhibit β-lactoglobulin glycosylation at appropriate concentrations. Circular dichroism spectroscopy and other experiments showed that the combined use of the two can better alleviate protein secondary structure changes and aggregation. They competitively bind to the same glycosylation site, synergistically resist oxidation, thereby inhibiting AGEs formation, and synergistically reducing oxidative stress, cell damage, and apoptosis at the cellular level. Therefore, the combined application of these two drugs has potential therapeutic value in intervening in diabetic complications.

The invention provides a dressing for promoting wound healing and a preparation method thereof. The method specifically comprises the following steps: (1) preparing sulfated carboxymethyl chitosan; (2) adding sulfated carboxymethyl chitosan, calcium peroxide and calcium peroxide into a sodium alginate aqueous solution, uniformly mixing, pouring into vegetable oil which is stirred at a high speed to prepare W / O emulsion, and centrifuging and freezing the emulsion to prepare sodium alginate embedded microspheres; and (3) adding the sodium alginate embedded microspheres into a sodium hyaluronate solution, then adding a cross-linking agent, pouring the obtained mixed solution into a mold, freezing and freeze-drying to prepare the dressing for promoting wound healing. The dressing disclosed by the invention is high in mechanical strength and good in air permeability, can locally release oxygen, promote vascularization and promote wound repair, and can be widely applied to difficult-to-heal wounds such as common wounds, burns, scalds and diabetic complications.

The invention discloses a traditional Chinese medicine formula for preventing and treating diabetic nephropathy. The important composition is prepared from the following raw material medicines: 100g of gynura divaricata, 100g of silybum marianum seeds, 100g of clerodendranthus spicatus, 60g of melastoma dodecandrum, 60g of horseradish tree leaves, 60g of sappan wood, 60g of pseudo-ginseng, 60g of ligusticum chuanxiong hort, 60g of leech, 60g of gardenia jasminoides, 60g of sweet potato pulp, 60g of centella asiatica and 60g of cottonrose hibiscus leaves. The traditional Chinese medicine composition is prepared into pills and granules, is a pure traditional Chinese medicine preparation, and has a special effect on treating the diabetic complication kidney. The traditional Chinese medicine composition can effectively inhibit and degrade blood muscle liver, urea nitrogen and blood toxins, can gradually restore the renal function of some mild and moderate diabetic nephropathy patients to normal, and can replace hemodialysis or reduce the number of dialysis times for some severe uremia patients.